Article citationsMore>>
Eagle, K.A., Guyton, R.A., Davidoff, R., Edwards, F.H., Ewy, G.A., Gardner, T.J., Hart, J.C., Herrmann, H.C., Hillis, L.D., Hutter Jr., A.M., Lytle, B.W., Marlow, R.A, Nugent, W.C., Orszulak, T.A., Antman, E.M., Smith Jr., S.C., Alpert, J.S., Anderson, J.L., Faxon, D.P., Fuster, V., Gibbons, R.J., Gregoratos, G., Halperin, J.L., Hiratzka, L.F. and Hunt, S.A. (2004) ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: Summary article: A report of the American college of cardiology/American heart association task force on practice guidelines (committee to update the 1999 guidelines for coronary artery bypass graft surgery). Circulation, 110, 1168-1176. doi:10.1161/01.CIR.0000138790.14877.7D
has been cited by the following article:
-
TITLE:
Unprotected left main coronary artery stenting with everolimus (Xience V) drug-eluting stents: A single center retrospective experience
AUTHORS:
Juan C. Fernandez-Guerrero, Juan A. Herrador, Manuel Guzman, Victor Aragon, Carmen Adamuz
KEYWORDS:
Percutaneous Coronary Interventions; “Off Label” Lesions; Prognosis
JOURNAL NAME:
World Journal of Cardiovascular Diseases,
Vol.3 No.2,
April
25,
2013
ABSTRACT:
Objectives: We sought to evaluate the efficacy and
safety of unrestricted implantation of everolimus eluting stent Xience V
(EES-XV) in a cohort of real- world patients with unprotected left main
coronary disease (ULMCD). Background: The second-generation EES-XV stent is
currently one of the most commonly used drug-eluting stents in clinical
practice. It has been shown to be superior to paclitaxel-eluting stents, but
its relative merits on unprotected left main coronary disease have been less
extensively assessed. Methods: Between 2007
and 2010, in this single-center registry, we evaluated the clinical
outcomes of 98 patients with ULMCD who underwent percutaneous coronary
intervention (PCI) with EES-XV. Results: There were no in-hospital deaths. At
25.63 ± 14.41 months of follow-up, 17 patients (17.3%) experienced major adverse
coronary event (MACE), death from cardiovascular disease (n = 6; 6.1%) and
target lesion revascularization (TLR; n = 7; 7.1%). The predictors of death
from cardiovascular disease were: previous PCI and left ventricular
dysfunction. The only predictor of TLR was the placement of 2 stents in the
left main coronary artery. Conclusions: In this single- center real-world
registry, we found that elective ULMCD stenting with EES-XV provided good
short-, medium- and long-term outcomes, with an estimated cumulative need for
TLR of 7.1%, a cardiac mortality rate of 6.1%, and a MACE rate of 17.3% at 2
years.
Related Articles:
-
Gerez Fernandes Martins, Gerez Martins
-
Habib Cakir, Funda Tor, Hasan Uncu, Ozcan Gur, Mehmet Acipayam, Ozsoyler Ibrahim
-
Mohammed Abd Elzaher Abd El Motaleb, Tamer Hikal, Mohammed Nabil Abd Al Jawad, Hani Metwaly, Mohsen Fadala
-
Montaser Elsawy Abd Elaziz, Eman Gomaa Saleh, Mohamed Gaber Elsayed, Bassem A. Hafez
-
Adymas Perdana, Mochamad Arif Nugroho, Suhartono Suhartono, Mochamad Ali Sobirin